title: Simultaneous screen for microsomal stability and metabolite profile by direct injection turbulent-laminar flow LC-LC and automated tandem mass spectrometry.
abstract: A LC-LC/MS/MS method has been developed that significantly increases the throughput in metabolism screening of drug candidates during lead optimization in discovery. This was accomplished by the reduction of sample preparation time through an on-line extraction of a drug and its metabolites from microsomal proteins using turbulent flow chromatography. Following its injection onto a column at turbulent flow, the drug and its metabolites are backwashed onto a reverse-phase column via on-line column switching and resolved chromatographically at a laminar flow of 2 mL/min. This tandem turbulent-laminar flow chromatographic system in a total cycle time of 8 min can achieve adequate separation of isomeric metabolites of venlafaxine, haloperidol, or adatanserin. Further improvement in throughput can be achieved by multiplexing both microsomal stability assessment and metabolite profiling into a single analysis. This is made possible by the ability of the ion-trap mass spectrometer to perform simultaneously multiple-reaction monitoring for microsomal stability and data-dependent multiple-stage mass spectrometric analysis for metabolite profiling within a single LC analysis. Such a LC-LC/MS/MS approach can dramatically shorten the time for providing metabolism feedback to the drug discovery process.
authors.affiliation: Drug Safety and Metabolism, Wyeth-Ayerst Research, Monmouth Junction, New Jersey 08852, USA. limh@war.wyeth.com
authors.forename: H K
authors.initials: HK
authors.lastname: Lim
authors.forename: K W
authors.initials: KW
authors.lastname: Chan
authors.forename: S
authors.initials: S
authors.lastname: Sisenwine
authors.forename: J A
authors.initials: JA
authors.lastname: Scatina
mesh_terms: D000818:Animals; D002853:Chromatography, Liquid / Q000295:instrumentation* / Q000379:methods*; D003511:Cyclohexanols / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000295:instrumentation* / Q000379:methods*; D006220:Haloperidol / Q000378:metabolism; D008862:Microsomes, Liver / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000032:analysis*; D010879:Piperazines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D004364:Pharmaceutical Preparations; D010879:Piperazines; D011743:Pyrimidines; C081272:WY 50324; D000069470:Venlafaxine Hydrochloride; D006220:Haloperidol